H3C6
gene geneOn this page
Also known as H3/dH3.1
Summary
H3C6 (H3 clustered histone 6, HGNC:4769) is a protein-coding gene on chromosome 6p22.2, encoding Histone H3.1 (P68431). Core component of nucleosome.
Histones are basic nuclear proteins that are responsible for the nucleosome structure of the chromosomal fiber in eukaryotes. Two molecules of each of the four core histones (H2A, H2B, H3, and H4) form an octamer, around which approximately 146 bp of DNA is wrapped in repeating units, called nucleosomes. The linker histone, H1, interacts with linker DNA between nucleosomes and functions in the compaction of chromatin into higher order structures. This gene is intronless and encodes a replication-dependent histone that is a member of the histone H3 family. Transcripts from this gene lack polyA tails but instead contain a palindromic termination element. This gene is found in the large histone gene cluster on chromosome 6.
Source: NCBI Gene 8353 — RefSeq curated summary.
At a glance
- GWAS associations: 13
- Clinical variants (ClinVar): 35 total
- MANE Select transcript:
NM_003532
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:4769 |
| Approved symbol | H3C6 |
| Name | H3 clustered histone 6 |
| Location | 6p22.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | H3/d, H3.1 |
| Ensembl gene | ENSG00000274750 |
| Ensembl biotype | protein_coding |
| OMIM | 602813 |
| Entrez | 8353 |
Gene structure
Transcript identifiers
Ensembl transcripts: 3 — 3 protein_coding
ENST00000614911, ENST00000634733, ENST00000876315
RefSeq mRNA: 2 — MANE Select: NM_003532
NM_001381999, NM_003532
CCDS: CCDS4596
Canonical transcript exons
ENST00000614911 — 1 exons
| Exon | Start | End |
|---|---|---|
| ENSE00003718370 | 26225135 | 26225616 |
Expression profiles
Bgee: expression breadth ubiquitous, 199 present calls, max score 87.13.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 129.9284 / max 4208.5190, expressed in 1636 samples.
FANTOM5 promoters (3 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 66496 | 118.7640 | 1017 |
| 66494 | 8.2624 | 1506 |
| 66493 | 2.9020 | 1135 |
Top tissues by expression
273 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| adrenal tissue | UBERON:0018303 | 87.13 | gold quality |
| esophagus squamous epithelium | UBERON:0006920 | 81.53 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 79.73 | gold quality |
| heart right ventricle | UBERON:0002080 | 79.33 | gold quality |
| sperm | CL:0000019 | 78.89 | silver quality |
| amniotic fluid | UBERON:0000173 | 78.82 | gold quality |
| apex of heart | UBERON:0002098 | 78.61 | gold quality |
| male germ cell | CL:0000015 | 76.51 | silver quality |
| epithelium of esophagus | UBERON:0001976 | 76.51 | gold quality |
| jejunal mucosa | UBERON:0000399 | 75.35 | gold quality |
| heart left ventricle | UBERON:0002084 | 75.33 | gold quality |
| cardiac ventricle | UBERON:0002082 | 75.30 | gold quality |
| pancreatic ductal cell | CL:0002079 | 75.29 | silver quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 75.14 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 75.04 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 74.35 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 72.89 | gold quality |
| squamous epithelium | UBERON:0006914 | 72.42 | gold quality |
| skeletal muscle tissue of rectus abdominis | UBERON:0004511 | 72.29 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 72.25 | gold quality |
| germinal epithelium of ovary | UBERON:0001304 | 72.04 | gold quality |
| right adrenal gland | UBERON:0001233 | 71.98 | gold quality |
| heart | UBERON:0000948 | 71.79 | gold quality |
| ileal mucosa | UBERON:0000331 | 71.25 | silver quality |
| biceps brachii | UBERON:0001507 | 71.16 | silver quality |
| duodenum | UBERON:0002114 | 69.94 | gold quality |
| right uterine tube | UBERON:0001302 | 69.82 | gold quality |
| stromal cell of endometrium | CL:0002255 | 69.61 | gold quality |
| adrenal gland | UBERON:0002369 | 68.59 | gold quality |
| calcaneal tendon | UBERON:0003701 | 68.29 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-GEOD-99795 | yes | 24.74 |
| E-ANND-3 | no | 2.01 |
Regulation
Is transcription factor: no
Literature-anchored findings (GeneRIF, showing 5)
- analysis of histone posttranslational modifications on H3.1 and H3.3 (PMID:17052464)
- This protein has been found differentially expressed in the temporal lobe from patients with schizophrenia. (PMID:19034380)
- there are significant alterations of H3K4me3 in minimal change nephrotic syndrome patients (PMID:19797895)
- analysis of the binding pattern of FOXA1 and FOXA3 and their relation to H3K4me3 in HepG2 cells (PMID:19919681)
- Combinatorial Histone H3 Modifications Are Dynamically Altered in Distinct Cell Cycle Phases. (PMID:33818074)
Cross-species orthologs
23 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | zgc:173552 | ENSDARG00000051737 |
| danio_rerio | si:ch1073-153i20.2 | ENSDARG00000105345 |
| danio_rerio | zgc:173552 | ENSDARG00000110909 |
| danio_rerio | si:ch211-113a14.27 | ENSDARG00000111396 |
| danio_rerio | si:ch211-113a14.20 | ENSDARG00000112131 |
| danio_rerio | zgc:173552 | ENSDARG00000112175 |
| danio_rerio | si:ch211-113a14.23 | ENSDARG00000114334 |
| drosophila_melanogaster | His3:CG33812 | FBGN0053812 |
| caenorhabditis_elegans | WBGENE00001876 | |
| caenorhabditis_elegans | WBGENE00001880 | |
| caenorhabditis_elegans | WBGENE00001883 | |
| caenorhabditis_elegans | WBGENE00001887 | |
| caenorhabditis_elegans | WBGENE00001891 | |
| caenorhabditis_elegans | WBGENE00001899 | |
| caenorhabditis_elegans | WBGENE00001901 | |
| caenorhabditis_elegans | WBGENE00001906 | |
| caenorhabditis_elegans | WBGENE00001914 | |
| caenorhabditis_elegans | WBGENE00001916 | |
| caenorhabditis_elegans | WBGENE00001919 | |
| caenorhabditis_elegans | WBGENE00001923 | |
| caenorhabditis_elegans | WBGENE00001929 | |
| caenorhabditis_elegans | WBGENE00001933 | |
| caenorhabditis_elegans | WBGENE00001937 |
Paralogs (20): CENPA (ENSG00000115163), H3-3B (ENSG00000132475), H3-3A (ENSG00000163041), H3-4 (ENSG00000168148), H3C13 (ENSG00000183598), H3-5 (ENSG00000188375), H3C12 (ENSG00000197153), H3C4 (ENSG00000197409), H3C14 (ENSG00000203811), H3C15 (ENSG00000203852), H3Y2 (ENSG00000268799), H3Y1 (ENSG00000269466), H3-7 (ENSG00000273213), H3C8 (ENSG00000273983), H3C11 (ENSG00000275379), H3C1 (ENSG00000275714), H3C7 (ENSG00000277775), H3C10 (ENSG00000278828), H3C2 (ENSG00000286522), H3C3 (ENSG00000287080)
Protein
Protein identifiers
Histone H3.1 — P68431 (reviewed: P68431)
Alternative names: Histone H3/a, Histone H3/b, Histone H3/c, Histone H3/d, Histone H3/f, Histone H3/h, Histone H3/i, Histone H3/j, Histone H3/k, Histone H3/l
All UniProt accessions (1): P68431
UniProt curated annotations — full annotation on UniProt →
Function. Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling.
Subunit / interactions. The nucleosome is a histone octamer containing two molecules each of H2A, H2B, H3 and H4 assembled in one H3-H4 heterotetramer and two H2A-H2B heterodimers. The octamer wraps approximately 147 bp of DNA. Interacts with TONSL; CHAF1A; CHAF1B; MCM2 and DNAJC9. Interacts with NASP; NASP is a histone chaperone that stabilizes and maintains a soluble pool of Histone H3-H4 dimers.
Subcellular location. Nucleus. Chromosome.
Post-translational modifications. Acetylation is generally linked to gene activation. Acetylation on Lys-10 (H3K9ac) impairs methylation at Arg-9 (H3R8me2s). Acetylation on Lys-19 (H3K18ac) and Lys-24 (H3K24ac) favors methylation at Arg-18 (H3R17me). Acetylation at Lys-123 (H3K122ac) by EP300/p300 plays a central role in chromatin structure: localizes at the surface of the histone octamer and stimulates transcription, possibly by promoting nucleosome instability. Citrullination at Arg-9 (H3R8ci) and/or Arg-18 (H3R17ci) by PADI4 impairs methylation and represses transcription. Asymmetric dimethylation at Arg-18 (H3R17me2a) by CARM1 is linked to gene activation. Symmetric dimethylation at Arg-9 (H3R8me2s) by PRMT5 is linked to gene repression. Asymmetric dimethylation at Arg-3 (H3R2me2a) by PRMT6 is linked to gene repression and is mutually exclusive with H3 Lys-5 methylation (H3K4me2 and H3K4me3). H3R2me2a is present at the 3’ of genes regardless of their transcription state and is enriched on inactive promoters, while it is absent on active promoters. Methylation at Lys-5 (H3K4me), Lys-37 (H3K36me) and Lys-80 (H3K79me) are linked to gene activation. Methylation at Lys-5 (H3K4me) facilitates subsequent acetylation of H3 and H4. Methylation at Lys-80 (H3K79me) is associated with DNA double-strand break (DSB) responses and is a specific target for TP53BP1. Methylation at Lys-10 (H3K9me) and Lys-28 (H3K27me) are linked to gene repression. Methylation at Lys-10 (H3K9me) is a specific target for HP1 proteins (CBX1, CBX3 and CBX5) and prevents subsequent phosphorylation at Ser-11 (H3S10ph) and acetylation of H3 and H4. Methylation at Lys-5 (H3K4me) and Lys-80 (H3K79me) require preliminary monoubiquitination of H2B at ‘Lys-120’. Methylation at Lys-10 (H3K9me) and Lys-28 (H3K27me) are enriched in inactive X chromosome chromatin. Monomethylation at Lys-57 (H3K56me1) by EHMT2/G9A in G1 phase promotes interaction with PCNA and is required for DNA replication. Phosphorylated at Thr-4 (H3T3ph) by VRK1. Phosphorylated at Thr-4 (H3T3ph) by HASPIN during prophase and dephosphorylated during anaphase. Phosphorylation at Ser-11 (H3S10ph) by AURKB is crucial for chromosome condensation and cell-cycle progression during mitosis and meiosis. In addition phosphorylation at Ser-11 (H3S10ph) by RPS6KA4 and RPS6KA5 is important during interphase because it enables the transcription of genes following external stimulation, like mitogens, stress, growth factors or UV irradiation and result in the activation of genes, such as c-fos and c-jun. Phosphorylation at Ser-11 (H3S10ph), which is linked to gene activation, prevents methylation at Lys-10 (H3K9me) but facilitates acetylation of H3 and H4. Phosphorylation at Ser-11 (H3S10ph) by AURKB mediates the dissociation of HP1 proteins (CBX1, CBX3 and CBX5) from heterochromatin. Phosphorylation at Ser-11 (H3S10ph) is also an essential regulatory mechanism for neoplastic cell transformation. Phosphorylated at Ser-29 (H3S28ph) by MAP3K20 isoform 1, RPS6KA5 or AURKB during mitosis or upon ultraviolet B irradiation. Phosphorylation at Thr-7 (H3T6ph) by PRKCB is a specific tag for epigenetic transcriptional activation that prevents demethylation of Lys-5 (H3K4me) by LSD1/KDM1A. At centromeres, specifically phosphorylated at Thr-12 (H3T11ph) from prophase to early anaphase, by DAPK3 and PKN1. Phosphorylation at Thr-12 (H3T11ph) by PKN1 or isoform M2 of PKM (PKM2) is a specific tag for epigenetic transcriptional activation that promotes demethylation of Lys-10 (H3K9me) by KDM4C/JMJD2C. Phosphorylation at Thr-12 (H3T11ph) by chromatin-associated CHEK1 regulates the transcription of cell cycle regulatory genes by modulating acetylation of Lys-10 (H3K9ac). Phosphorylation at Tyr-42 (H3Y41ph) by JAK2 promotes exclusion of CBX5 (HP1 alpha) from chromatin. Monoubiquitinated at Lys-15 (H3K14ub), Lys-19 (H3K18ub) and Lys-24 (H3K23ub) by UHRF1 and HLTF at hemimethylated DNA sites following DNA replication, promoting recruitment of DNMT1 DNA methyltransferase and replication-coupled DNA methylation maintenance. Monoubiquitinated by RAG1 in lymphoid cells, monoubiquitination is required for V(D)J recombination. Ubiquitinated by the CUL4-DDB-RBX1 complex in response to ultraviolet irradiation. This may weaken the interaction between histones and DNA and facilitate DNA accessibility to repair proteins. Lysine deamination at Lys-5 (H3K4all) to form allysine is mediated by LOXL2. Allysine formation by LOXL2 only takes place on H3K4me3 and results in gene repression. Crotonylation (Kcr) is specifically present in male germ cells and marks testis-specific genes in post-meiotic cells, including X-linked genes that escape sex chromosome inactivation in haploid cells. Crotonylation marks active promoters and enhancers and confers resistance to transcriptional repressors. It is also associated with post-meiotically activated genes on autosomes. Butyrylation of histones marks active promoters and competes with histone acetylation. It is present during late spermatogenesis. Succinylation at Lys-80 (H3K79succ) by KAT2A takes place with a maximum frequency around the transcription start sites of genes. It gives a specific tag for epigenetic transcription activation. Desuccinylation at Lys-123 (H3K122succ) by SIRT7 in response to DNA damage promotes chromatin condensation and double-strand breaks (DSBs) repair. Serine ADP-ribosylation by PARP1 or PARP2 constitutes the primary form of ADP-ribosylation of proteins in response to DNA damage. Serine ADP-ribosylation at Ser-11 (H3S10ADPr) promotes recruitment of CHD1L. H3S10ADPr is mutually exclusive with phosphorylation at Ser-11 (H3S10ph) and impairs acetylation at Lys-10 (H3K9ac). Serotonylated by TGM2 at Gln-6 (H3Q5ser) during serotonergic neuron differentiation. H3Q5ser is associated with trimethylation of Lys-5 (H3K4me3) and enhances general transcription factor IID (TFIID) complex-binding to H3K4me3, thereby facilitating transcription. Dopaminylated by TGM2 at Gln-6 (H3Q5dop) in ventral tegmental area (VTA) neurons. H3Q5dop mediates neurotransmission-independent role of nuclear dopamine by regulating relapse-related transcriptional plasticity in the reward system. Lactylated in macrophages by EP300/P300 by using lactoyl-CoA directly derived from endogenous or exogenous lactate, leading to stimulates gene transcription.
Disease relevance. Glioma (GLM) [MIM:137800] Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes. The gene represented in this entry is involved in disease pathogenesis. HIST1H3B mutations affecting residue Lys-28 involved in post-translational modifications of histone H3.1 are recurrent in malignant, aggressive gliomas including pediatric non-brain stem glioblastoma and diffuse intrinsic pontine glioma (DIPG). The mechanism through which mutations lead to tumorigenesis involves altered histone methylation, impaired regulation of Polycomb repressive complex 2 (PRC2) activity, and aberrant epigenetic regulation of gene expression. HIST1H3B or HIST1H3C mutations affecting residue Lys-37 of histone H3.1 are involved in the pathogenesis of pediatric undifferentiated soft tissue sarcomas. The mechanism through which mutations lead to tumorigenesis involves altered histones methylation with gain of global H3K27 methylation, altered Polycomb repressive complex 1 (PRC1) activity, aberrant epigenetic regulation of gene expression and impaired differentiation of mesenchimal progenitor cells.
Miscellaneous. This histone is only present in mammals and is enriched in acetylation of Lys-15 and dimethylation of Lys-10 (H3K9me2).
Similarity. Belongs to the histone H3 family.
RefSeq proteins (2): NP_001368928, NP_003523* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000164 | Histone_H3/CENP-A | Family |
| IPR007125 | H2A/H2B/H3 | Domain |
| IPR009072 | Histone-fold | Homologous_superfamily |
Pfam: PF00125
UniProt features (146 total): modified residue 120, strand 8, sequence conflict 4, helix 4, cross-link 3, sequence variant 3, initiator methionine 1, chain 1, lipid moiety-binding region 1, region of interest 1
Structure
Experimental structures (PDB)
548 structures, top 30 by resolution.
| PDB | Method | Resolution (Å) |
|---|---|---|
| 5SVY | X-RAY DIFFRACTION | 1.05 |
| 2V89 | X-RAY DIFFRACTION | 1.1 |
| 5SZC | X-RAY DIFFRACTION | 1.19 |
| 5SZB | X-RAY DIFFRACTION | 1.2 |
| 6BHD | X-RAY DIFFRACTION | 1.25 |
| 4UP0 | X-RAY DIFFRACTION | 1.28 |
| 5WXH | X-RAY DIFFRACTION | 1.3 |
| 5FFV | X-RAY DIFFRACTION | 1.3 |
| 4L7X | X-RAY DIFFRACTION | 1.35 |
| 6BHE | X-RAY DIFFRACTION | 1.35 |
| 6BHI | X-RAY DIFFRACTION | 1.4 |
| 3ASL | X-RAY DIFFRACTION | 1.41 |
| 5TDR | X-RAY DIFFRACTION | 1.42 |
| 2RI7 | X-RAY DIFFRACTION | 1.45 |
| 4X3K | X-RAY DIFFRACTION | 1.45 |
| 6BHG | X-RAY DIFFRACTION | 1.45 |
| 5GH9 | X-RAY DIFFRACTION | 1.45 |
| 3V43 | X-RAY DIFFRACTION | 1.47 |
| 5JIY | X-RAY DIFFRACTION | 1.48 |
| 8IJ0 | X-RAY DIFFRACTION | 1.52 |
| 3RIY | X-RAY DIFFRACTION | 1.55 |
| 5SVX | X-RAY DIFFRACTION | 1.56 |
| 2VPG | X-RAY DIFFRACTION | 1.6 |
| 4LK9 | X-RAY DIFFRACTION | 1.6 |
| 4Y6L | X-RAY DIFFRACTION | 1.6 |
| 5T1I | X-RAY DIFFRACTION | 1.6 |
| 5U2J | X-RAY DIFFRACTION | 1.6 |
| 7CFP | X-RAY DIFFRACTION | 1.6 |
| 7CFQ | X-RAY DIFFRACTION | 1.6 |
| 6V41 | X-RAY DIFFRACTION | 1.6 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P68431-F1 | 86.95 | 0.71 |
Antibody-complex structures (SAbDab): 19 — 4YHP, 4YHZ, 7K5X, 7K5Y, 7K60, 7K61, 7K63, 7U0G, 7U0I, 7U0J, 8DK5, 8EVG, 8EVH, 8EVI, 8EVJ, 8SPS, 8SPU, 8SYP, 8VFX
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (124): 5, 80, 80, 80, 80, 80, 80, 80, 80, 80, 80, 5, 81, 87, 108, 116, 116, 123, 123, 123 …
Function
Pathways and Gene Ontology
Reactome pathways
48 pathways
| ID | Pathway |
|---|---|
| R-HSA-1266695 | Interleukin-7 signaling |
| R-HSA-1912408 | Pre-NOTCH Transcription and Translation |
| R-HSA-201722 | Formation of the beta-catenin:TCF transactivating complex |
| R-HSA-212300 | PRC2 methylates histones and DNA |
| R-HSA-2299718 | Condensation of Prophase Chromosomes |
| R-HSA-2559580 | Oxidative Stress Induced Senescence |
| R-HSA-2559582 | Senescence-Associated Secretory Phenotype (SASP) |
| R-HSA-3214815 | HDACs deacetylate histones |
| R-HSA-3214841 | PKMTs methylate histone lysines |
| R-HSA-3214842 | HDMs demethylate histones |
| R-HSA-3214847 | HATs acetylate histones |
| R-HSA-3214858 | RMTs methylate histone arginines |
| R-HSA-3247509 | Chromatin modifying enzymes |
| R-HSA-427359 | SIRT1 negatively regulates rRNA expression |
| R-HSA-427389 | ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression |
| R-HSA-427413 | NoRC negatively regulates rRNA expression |
| R-HSA-5250924 | B-WICH complex positively regulates rRNA expression |
| R-HSA-5334118 | DNA methylation |
| R-HSA-5578749 | Transcriptional regulation by small RNAs |
| R-HSA-5617472 | Activation of anterior HOX genes in hindbrain development during early embryogenesis |
| R-HSA-5625886 | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 |
| R-HSA-68616 | Assembly of the ORC complex at the origin of replication |
| R-HSA-73728 | RNA Polymerase I Promoter Opening |
| R-HSA-73772 | RNA Polymerase I Promoter Escape |
| R-HSA-8936459 | RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function |
| R-HSA-8939236 | RUNX1 regulates transcription of genes involved in differentiation of HSCs |
| R-HSA-9018519 | Estrogen-dependent gene expression |
| R-HSA-912446 | Meiotic recombination |
| R-HSA-9609690 | HCMV Early Events |
| R-HSA-9610379 | HCMV Late Events |
MSigDB gene sets: 196 (showing top):
REACTOME_MEIOTIC_RECOMBINATION, GOBP_CHROMOSOME_ORGANIZATION, REACTOME_DNA_REPLICATION, REACTOME_SIGNALING_BY_NOTCH, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, MORF_BRCA1, GOBP_TELOMERE_ORGANIZATION, MORF_RAD51L3, REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS, GOBP_NEGATIVE_REGULATION_OF_GENE_EXPRESSION_EPIGENETIC, MODULE_379, MORF_THPO, MODULE_88, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN
GO Biological Process (5): chromatin organization (GO:0006325), nucleosome assembly (GO:0006334), telomere organization (GO:0032200), epigenetic regulation of gene expression (GO:0040029), gene expression (GO:0010467)
GO Molecular Function (5): DNA binding (GO:0003677), structural constituent of chromatin (GO:0030527), cadherin binding (GO:0045296), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515)
GO Cellular Component (8): nucleosome (GO:0000786), extracellular region (GO:0005576), nucleus (GO:0005634), nucleoplasm (GO:0005654), membrane (GO:0016020), protein-containing complex (GO:0032991), extracellular exosome (GO:0070062), chromosome (GO:0005694)
Reactome top-level categories
Rollup of top-12 pathways:
| Category | Pathways |
|---|---|
| Chromatin modifying enzymes | 5 |
| Epigenetic regulation of gene expression | 2 |
| Cellular Senescence | 2 |
| Negative epigenetic regulation of rRNA expression | 2 |
| Positive epigenetic regulation of rRNA expression | 2 |
| Signaling by Interleukins | 1 |
| Pre-NOTCH Expression and Processing | 1 |
| TCF dependent signaling in response to WNT | 1 |
| Mitotic Prophase | 1 |
| Chromatin organization | 1 |
| Gene Silencing by RNA | 1 |
| Activation of HOX genes during differentiation | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 3 |
| chromatin | 2 |
| cellular component organization | 1 |
| chromatin organization | 1 |
| nucleosome organization | 1 |
| protein-DNA complex assembly | 1 |
| chromosome organization | 1 |
| chromatin remodeling | 1 |
| regulation of gene expression | 1 |
| macromolecule biosynthetic process | 1 |
| nucleic acid binding | 1 |
| structural molecule activity | 1 |
| cell adhesion molecule binding | 1 |
| protein dimerization activity | 1 |
| binding | 1 |
| protein-DNA complex | 1 |
| intracellular membrane-bounded organelle | 1 |
| nuclear lumen | 1 |
| cellular_component | 1 |
| extracellular vesicle | 1 |
| intracellular membraneless organelle | 1 |
Protein interactions and networks
STRING
0 interactions, top by confidence (×1000):
IntAct
448 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| H3C1 | CHAF1A | psi-mi:“MI:0914”(association) | 0.910 |
| NASP | H3C1 | psi-mi:“MI:0915”(physical association) | 0.910 |
| SUZ12 | EED | psi-mi:“MI:0914”(association) | 0.910 |
| H3C1 | H4C16 | psi-mi:“MI:0915”(physical association) | 0.890 |
| H4C16 | H3C1 | psi-mi:“MI:0407”(direct interaction) | 0.890 |
| H2AC4 | H2BC11 | psi-mi:“MI:0915”(physical association) | 0.850 |
| H3C1 | RBBP4 | psi-mi:“MI:0914”(association) | 0.840 |
| H3C1 | DNAJC9 | psi-mi:“MI:0915”(physical association) | 0.810 |
| NASP | H3C1 | psi-mi:“MI:0915”(physical association) | 0.780 |
| H3C1 | NASP | psi-mi:“MI:0915”(physical association) | 0.780 |
| H3C1 | HAT1 | psi-mi:“MI:0914”(association) | 0.770 |
| H2AZ1 | ZNHIT1 | psi-mi:“MI:0914”(association) | 0.770 |
| H3C1 | MCM2 | psi-mi:“MI:0915”(physical association) | 0.710 |
| H3C1 | MCM2 | psi-mi:“MI:0914”(association) | 0.710 |
| KDM1A | psi-mi:“MI:0915”(physical association) | 0.700 | |
| HTT | H3C1 | psi-mi:“MI:0915”(physical association) | 0.700 |
BioGRID (3102): HIST1H3A (Affinity Capture-Western), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3H (Two-hybrid), FBLIM1 (Two-hybrid), HIST1H3A (Reconstituted Complex), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), HIST1H3A (Biochemical Activity), KAT2B (Co-localization), HIST1H3A (Biochemical Activity)
ESM2 similar proteins: A1CP80, A1D240, A2QRR5, A3LXD5, A4RCX7, A5DFC5, A5DG57, P02299, P07041, P08898, P09988, P0CO04, P0CO05, P10651, P23753, P61832, P61834, P61835, P68431, P68432, P68433, P84227, P84228, P84229, P84230, P84231, P84233, P84234, P84235, P84236, P84237, P84238, P84239, Q0D0E8, Q0UY45, Q1E225, Q28D37, Q2UCQ0, Q4IER8, Q4QRF4
Diamond homologs: A1CP80, A1D240, A2QRR5, A2Y533, A3GHN6, A3LXD5, A4RCX7, A5DFC5, A5DG57, A5DWE2, A5E094, C0HL66, C0HL67, P02299, P02301, P07041, P08903, P09988, P0CO04, P0CO05, P10651, P23753, P59226, P61830, P61831, P61832, P61833, P61834, P61835, P61836, P68427, P68428, P68429, P68430, P68431, P68432, P68433, P69071, P69072, P69073
SIGNOR signaling
75 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| AURKB | “down-regulates activity” | H3C1 | phosphorylation |
| AURKB | “up-regulates activity” | H3C1 | phosphorylation |
| AURKC | “up-regulates activity” | H3C1 | phosphorylation |
| RPS6KA3 | “down-regulates activity” | H3C1 | phosphorylation |
| RPS6KA5 | “down-regulates activity” | H3C1 | phosphorylation |
| TGM2 | unknown | H3C1 | phosphorylation |
| PBK | unknown | H3C1 | phosphorylation |
| MAML1 | “down-regulates activity” | H3C1 | acetylation |
| PIM1 | “down-regulates activity” | H3C1 | phosphorylation |
| VRK1 | unknown | H3C1 | phosphorylation |
| MAPK14 | unknown | H3C1 | phosphorylation |
| PRKCD | “up-regulates activity” | H3C1 | phosphorylation |
| PIM | “down-regulates activity” | H3C1 | phosphorylation |
| KDM6A | “down-regulates activity” | H3C1 | demethylation |
| KDM6B | “down-regulates activity” | H3C1 | demethylation |
| CTNNB1 | “up-regulates activity” | H3C1 | |
| “Polycomb repressive complex 2” | “up-regulates activity” | H3C1 | methylation |
| KDM4B | “down-regulates activity” | H3C1 | demethylation |
| KDM4C | “down-regulates activity” | H3C1 | demethylation |
| SETDB2 | “up-regulates activity” | H3C1 | methylation |
| KDM5A | “up-regulates activity” | H3C1 | demethylation |
| KDM5B | “up-regulates activity” | H3C1 | demethylation |
| KDM5C | “up-regulates activity” | H3C1 | demethylation |
| KDM5D | “up-regulates activity” | H3C1 | demethylation |
| “Set1-Ash2 HMT complex” | “down-regulates activity” | H3C1 | methylation |
Enriched among interaction partners
Reactome pathways and GO biological processes over-represented among this gene’s 123 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.
Reactome pathways:
| Pathway | Partners | Fold | FDR |
|---|---|---|---|
| Regulation of PTEN gene transcription | 9 | 19.4× | 4e-08 |
| Defective pyroptosis | 10 | 18.9× | 1e-08 |
| Negative Regulation of CDH1 Gene Transcription | 13 | 18.8× | 7e-11 |
| PRC2 methylates histones and DNA | 10 | 18.4× | 1e-08 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 10 | 18.4× | 1e-08 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 5 | 18.1× | 8e-05 |
| ChAHP complex assembly | 8 | 17.8× | 4e-07 |
| Transcriptional Regulation by E2F6 | 5 | 17.6× | 9e-05 |
GO biological processes:
| GO term | Partners | Fold | FDR |
|---|---|---|---|
| heterochromatin formation | 10 | 24.6× | 3e-09 |
| nucleosome assembly | 17 | 23.0× | 8e-16 |
| chromatin organization | 12 | 11.4× | 1e-07 |
| chromatin remodeling | 15 | 10.5× | 3e-09 |
| DNA replication | 6 | 9.5× | 5e-03 |
| DNA repair | 13 | 8.0× | 2e-06 |
Disease & clinical
Clinical variants and AI predictions
ClinVar
35 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 35 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
407 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 6:26225068:G:T | donor_gain | 0.9900 |
| 6:26225559:G:GT | donor_gain | 0.9900 |
| 6:26225569:GTTT:G | donor_gain | 0.9900 |
| 6:26225570:TTTT:T | donor_gain | 0.9900 |
| 6:26225553:G:GT | donor_gain | 0.9800 |
| 6:26225553:G:T | donor_gain | 0.9800 |
| 6:26225572:T:G | donor_gain | 0.9800 |
| 6:26225572:T:TG | donor_gain | 0.9800 |
| 6:26224304:GG:G | donor_gain | 0.9700 |
| 6:26224305:GG:G | donor_gain | 0.9700 |
| 6:26224305:GGT:G | donor_loss | 0.9700 |
| 6:26224306:GTG:G | donor_loss | 0.9700 |
| 6:26224307:T:A | donor_loss | 0.9700 |
| 6:26224285:T:G | donor_gain | 0.9600 |
| 6:26224308:GA:G | donor_loss | 0.9600 |
| 6:26224309:A:AC | donor_loss | 0.9600 |
| 6:26224306:G:GG | donor_gain | 0.9500 |
| 6:26224310:G:C | donor_loss | 0.9500 |
| 6:26225437:G:GT | donor_gain | 0.9400 |
| 6:26225555:A:T | donor_gain | 0.9400 |
| 6:26225067:G:GT | donor_gain | 0.9300 |
| 6:26224285:TTAAG:T | donor_gain | 0.9200 |
| 6:26225558:GGGC:G | donor_gain | 0.9200 |
| 6:26227019:G:T | acceptor_gain | 0.9200 |
| 6:26224894:CTTTG:C | acceptor_loss | 0.8800 |
| 6:26224895:TTTG:T | acceptor_loss | 0.8800 |
| 6:26224896:TTGCA:T | acceptor_loss | 0.8800 |
| 6:26224897:TGCA:T | acceptor_loss | 0.8800 |
| 6:26224898:GC:G | acceptor_loss | 0.8800 |
| 6:26224899:C:G | acceptor_loss | 0.8800 |
AlphaMissense
0 scored. Top likely-pathogenic:
dbSNP variants (sampled 300 via entrez): RS1000281232 (6:26223398 G>A,C,T), RS1000720827 (6:26225262 G>A,C,T), RS1001320198 (6:26224749 G>A), RS1001895118 (6:26222627 T>C), RS1003163401 (6:26223886 T>C), RS1003540614 (6:26226718 C>T), RS1004109225 (6:26222990 A>C), RS1004963738 (6:26226191 A>G,T), RS1005196400 (6:26224760 C>T), RS1005343293 (6:26226005 T>C), RS1005392951 (6:26224455 C>G), RS1005837964 (6:26222957 T>C), RS1005961505 (6:26227549 T>A,G), RS1006406633 (6:26227844 G>A), RS1006774559 (6:26223891 G>A)
Disease associations
OMIM: gene MIM:602813 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
13 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004521_113 | Autism spectrum disorder or schizophrenia | 3.000000e-19 |
| GCST004521_142 | Autism spectrum disorder or schizophrenia | 2.000000e-09 |
| GCST004521_169 | Autism spectrum disorder or schizophrenia | 4.000000e-14 |
| GCST004521_69 | Autism spectrum disorder or schizophrenia | 8.000000e-24 |
| GCST004521_83 | Autism spectrum disorder or schizophrenia | 1.000000e-13 |
| GCST007294_143 | Body fat distribution (trunk fat ratio) | 5.000000e-29 |
| GCST007294_82 | Body fat distribution (trunk fat ratio) | 1.000000e-48 |
| GCST007295_120 | Body fat distribution (leg fat ratio) | 2.000000e-46 |
| GCST007295_91 | Body fat distribution (leg fat ratio) | 1.000000e-26 |
| GCST010141_1 | Beef consumption | 7.000000e-13 |
| GCST010143_19 | Meat-related diet | 5.000000e-13 |
| GCST010143_31 | Meat-related diet | 7.000000e-09 |
| GCST010143_5 | Meat-related diet | 4.000000e-09 |
EFO canonical traits (2, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004341 | body fat distribution |
| EFO:0008111 | diet measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
Binding affinities (BindingDB)
3 measured of 6 human assays (6 total across all organisms); most potent 3 below. Values come from heterogeneous assays and are not directly comparable.
| Ligand | Measure | Value | Patent |
|---|---|---|---|
| N-hydroxy-3-(2-phenethyl-1-(2-(piperidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide | EC50 | 500 nM | US-10201527: Benzimidazole derivatives: preparation and pharmaceutical applications |
| 3-(1-(3-(dimethylamino)-2,2-dimethylpropyl)-2-phenethyl-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide | EC50 | 1100 nM | US-10201527: Benzimidazole derivatives: preparation and pharmaceutical applications |
| N-hydroxy-3-(2-phenethyl-1-(3,4,5-trimethoxybenzyl)-1H-benzo[d]imidazol-5-yl)acrylamide | EC50 | 1700 nM | US-10201527: Benzimidazole derivatives: preparation and pharmaceutical applications |
CTD chemical–gene interactions
34 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | increases methylation, affects cotreatment, decreases expression | 5 |
| sodium arsenite | decreases expression, increases expression | 3 |
| Air Pollutants | decreases expression, increases abundance | 2 |
| bisphenol A | decreases expression | 1 |
| 2-methyl-4-isothiazolin-3-one | decreases expression | 1 |
| tris(1,3-dichloro-2-propyl)phosphate | decreases expression | 1 |
| S-(1,2-dichlorovinyl)cysteine | affects response to substance, increases expression | 1 |
| perfluoro-n-nonanoic acid | decreases expression | 1 |
| 2-palmitoylglycerol | increases expression | 1 |
| entinostat | decreases expression | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | affects cotreatment, decreases expression | 1 |
| dorsomorphin | decreases expression, affects cotreatment | 1 |
| NSC 689534 | affects binding, increases expression | 1 |
| (+)-JQ1 compound | decreases expression | 1 |
| Bortezomib | increases response to substance, decreases expression | 1 |
| Vorinostat | decreases expression | 1 |
| Coal | decreases expression, increases abundance | 1 |
| Copper | affects binding, increases expression | 1 |
| Dichlorodiphenyl Dichloroethylene | decreases expression | 1 |
| Demecolcine | increases expression | 1 |
| Dimethyl Sulfoxide | affects expression | 1 |
| Doxorubicin | increases expression | 1 |
| Estradiol | decreases expression | 1 |
| Formaldehyde | increases expression | 1 |
| Hydrogen Peroxide | affects cotreatment, increases expression | 1 |
| Lipopolysaccharides | affects response to substance, increases expression | 1 |
| Methyl Methanesulfonate | increases expression | 1 |
| Smoke | decreases expression, increases abundance | 1 |
| Theophylline | affects cotreatment, increases expression | 1 |
| Urethane | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.